Development of an electronic decision aid tool to facilitate mainstream genetic testing in ovarian cancer patients
Kristen M. Shannon(Massachusetts General Hospital), Karen Sepucha(Massachusetts General Hospital), Erica Blouch(Massachusetts General Hospital), Margaret M. Emmet(Massachusetts General Hospital), Jessica Jonas(Massachusetts General Hospital), Daniel C. Chung(Massachusetts General Hospital), Mackenzie Wooters(Massachusetts General Hospital), Devanshi Patel(Massachusetts General Hospital), Meredith Seidel(Massachusetts General Hospital), Carly F. Grant(Massachusetts General Hospital), Stephanie R. Hicks(Massachusetts General Hospital)
Cited by 2
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k